Contact us EN FR

Sarepta and Lysogene Announce Exclusive License Agreement for LYS-SAF302, a Late-stage Gene Therapy for the Treatment of MPS IIIA, and Grant of Option Rights to an Additional CNS Gene Therapy Candidate

Latest tweet

Get in touch

Follow us

Join our mailing list

arrow-left arrow-right calendar contact download facebook linkedin location play reset rss twitter youtube